FGF2 and melanoma: Inhibition of bFGF mitogenic activity with bFGF-binding peptide may reverse the effects of bFGF and lead to suppression of proliferation, cell cycle arrest at G0/G1 phase, reduction of phospho-ERK1/2 levels in the bFGF-stimulated cells of colon cancer [17], leukemia [18] and melanoma [19].